Halozyme Therapeutics Inc. (HALO)
Halozyme Just Bought Its Next Decade Of Growth
Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for ≤2 mL self-injections, complementing ENHANZE rather than cannibalizing it. Existing partners like Lilly, Argenx, and J&J are already aligned, with first-in-human Hypercon studies expected within 12–15 months.
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside
Halozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momentum.
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Rob, and I will be your conference operator today.
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Identify Superstar Stocks Like Halozyme with Money Flows
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
